Charles H.Arnett Ph.D. (Charlie)

IP Legal Intern

Washington + 1.202.879.3896

Collegati

Condividi

Dr. Charles (Charlie) Arnett prosecutes patent applications and manages global patent portfolios in the pharmaceutical and biotech industries. Charlie assists clients with a broad range of services, including preparation and prosecution of patent applications, management of worldwide patent portfolio strategies, performance of due diligence investigations, patentability and validity assessments, and freedom-to-operate analysis. Representative clients include Celgene Corporation, REGENXBIO, and Nuvalent.

Prior to joining Jones Day, Charlie was an NSF Graduate Research Fellow at the California Institute of Technology, where he synthesized and studied model complexes of the nitrogenase active site. He also contributed to the development of a Cu-catalyzed protocol for C-H etherification as an undergraduate at Georgetown University. Charlie has coauthored several peer-reviewed scientific publications, four of which are published in the Journal of the American Chemical Society.

Esperienze

  • Nuvalent establishes global patent portfolios for small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective tyrosine kinase inhibitorsJones Day represents Nuvalent, Inc. in the establishment and prosecution of global patent portfolios related to small molecule ROS1-selective inhibitors, ALK-selective inhibitors, and HER2-selective tyrosine kinase inhibitors for the treatment of cancer.
  • Royalty Pharma acquires Oxlumo™ royalty interest from DicernaJones Day advised Royalty Pharma in the acquisition of an interest in Dicerna’s royalty in Dicerna’s OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments.
    •

    Prima di procedere all'invio, si prega di notare:

    il contenuto del presente sito web è a scopo esclusivamente informativo e non può essere considerato un parere legale o altro tipo di consulenza professionale. L'invio o la ricezione della presente email non è atta ad instaurare alcun rapporto cliente/avvocato. Le informazioni inviate tramite questa funzione al nostro Studio non saranno coperte da vincolo di riservatezza o confidenzialità fintanto che non ci sia stato conferito e non sia stato da noi accettato un incarico professionale. Inviando il messaggio confermate di aver preso visione e accettato il contenuto di questa informativa.